MedTrace Logo

Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma

NCT04189679 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2024-01-17

No results posted yet for this study

Summary

Immune checkpoints inhibitors (ICI) are becoming new standards of care for Non-Small Cell Lung Carcinoma (NSCLC) treatment. To date, no powerful predictive biomarker of response has been found.

The investigators hypothesize that metabolomics profile could represent a potent biomarker of response to ICI

Conditions

  • Non Small Cell Lung Cancer

Interventions

OTHER

Immune signature in serum associated to the metabolic signature

Immune signature in serum associated to the metabolic signature

GENETIC

Meta-genomic signature of intestinal flora

Meta-genomic signature of intestinal flora

Sponsors & Collaborators

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Anne-Claire Toffart, Dr · University Hospital, Grenoble

  • Dalil Hannani, PhD · Medicine University, Grenoble

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-03
Primary Completion
2023-01-27
Completion
2023-01-27

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04189679 on ClinicalTrials.gov